Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

blank

 

Recent News and Articles on the Keywords: generalized anxiety + anxiety disorder + duloxetine  Related to the article below (Last Update: 7/1/2008)

European CHMP Issues Positive Opinion on Cymbalta for the ...
Earthtimes (press release), UK - Jun 26, 2008
Patients report that episodes of generalized anxiety disorder are often brought on, or worsened, by stressful life events.(14) While duloxetine's mechanism ...LLY
Boehringer, Eli Lilly's Cymbalta recommended by EU's CHMP for ...
Forbes, NY - Jun 27, 2008
... has recommended European Union approval for the use of the Cymbalta drug, jointly developed with Eli Lilly & Co., against general anxiety disorder. ...
Lilly's anxiety drug wins EU positive opinion Trading Markets (press release)
EU agency backs Eli Lilly's Cymbalta for wider use Reuters
Eli Lilly and Boehringer announce positive opinion from European ... RTT News
Forbes
all 16 news articles »  LLY - OTC:CMTX

The Money Times
FDA Approves Cymbalta(R) for the Management of Fibromyalgia
FOXBusiness - Jun 16, 2008
Cymbalta is approved to treat major depressive disorder and generalized anxiety disorder, and to manage diabetic peripheral neuropathic pain and ...
Cymbalta Approved for Fibromyalgia U.S. News & World Report
FDA approves Cymbalta for Fibromyalgia United Press International
Eli Lilly: FDA nod adds gravitas to fibromyalgia Trading Markets (press release)
Pharma Times (subscription) - istockAnalyst.com
all 78 news articles »  LLY
Patients Taking Cymbalta(R) Reported Reduced Pain Severity of ...
Earthtimes (press release), UK - Jun 13, 2008
Cymbalta is approved to treat major depressive disorder and generalized anxiety disorder and manage diabetic peripheral neuropathic pain. ...
Eli Lilly: Drug treats knee osteoarthritis pain CNNMoney.com
Clinical trial results encouraging for Lilly drug Indianapolis Business Journal
all 18 news articles »  LLY
Patients Taking Cymbalta(R) Reported Reduced Pain Severity Of ...
Medical News Today (press release), UK - Jun 14, 2008
Cymbalta is approved to treat major depressive disorder and generalized anxiety disorder and manage diabetic peripheral neuropathic pain. ...
FDA Approves Duloxetine HCl for the Management of Fibromyalgia
DG News - Jun 16, 2008
... peripheral neuropathic pain (DPNP) and the treatment of major depressive disorder and generalised anxiety disorder, all in adults aged 18 years and older.
FDA Approvals: Cymbalta
Medscape (subscription) - Jun 19, 2008
Duloxetine previously was approved for the treatment of diabetic peripheral neuropathic pain, depression, and generalized anxiety disorder.
FDA approves Cymbalta for fibromyalgia
Prescribing Reference, New York - Jun 16, 2008
Cymbalta is already indicated for the acute and maintenance treatment of major depressive disorder, the acute treatment of generalized anxiety disorder, ...
Behavioural issues: A cure for everything
Belfast Telegraph, United Kingdom - Jun 5, 2008
Anxiety disorder is characterised by a fear of social or performance situations, and sufferers are often concerned that they will do or say something ...
FDA Approves Duloxetene (Cymbalta) for Fibromyalgia
MedPage Today, NJ - Jun 16, 2008
Duloxetine is also indicated in adults for major depressive disorder, general anxiety, and peripheral diabetic neuropathy. The added indication was approval ...
Source: Google News

Duloxetine vs. placebo in patients with painful diabetic neuropathy -
DJ Goldstein, Y Lu, MJ Detke, TC Lee, S Iyengar - Pain, 2005 - Elsevier
... objective was to evaluate the efficacy of duloxetine 20, 60 ... of MDD, depression-partial
remission, dysthymic disorder, generalized anxiety disorder, alcohol or ...

Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, …
M Rynn, J Russell, J Erickson, MJ Detke, S Ball, J … - Depress Anxiety, 2007 - ncbi.nlm.nih.gov
... to read Efficacy and safety of duloxetine in the treatment of generalized anxiety
disorder: a flexible-dose, progressive-titration, placebo-controlled trial. ...

Organisational downsizing, sickness absence, and mortality: 10-town prospective cohort study. -
J Vahtera, M Kivimaki, J Pentti, A Linna, M … - British Medical Journal (Clinical Research edition), 2004 - pt.wkhealth.com
... 288, Escitalopram in the Treatment of Panic Disorder: A Randomized, Double ... Compared
With Paroxetine Monotherapy for Generalized Social Anxiety Disorder. ...

… -based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the … -
DS Baldwin, IM Anderson, DJ Nutt, B Bandelow, A … - Journal of Psychopharmacology, 2005 - jop.sagepub.com
... have considered those guidelines developed by the National Institute for Clinical
Excellence for generalized anxiety disorder, panic disorder, post-traumatic ...

Current review of the comorbidity of affective, anxiety, and substance use disorders. -
H Myrick, K Brady - Current Opinion in Psychiatry, 2003 - co-psychiatry.com
... As with panic disorder, nonpharmacologic treatments for GAD ... of OCD in the general
population [1 ... following sections, specific anxiety disorders which commonly co ...

[CITATION] A Double-Blind, Randomized Multicenter Trial Comparing Duloxetine with Placebo in the Management of … -
J Raskin, YL Pritchett, F Wang, DN D'Souza, AL … - Pain Medicine, 2005 - Blackwell Synergy
... (2007) Efficacy of duloxetine in the treatment of generalized anxiety disorder
in patients with clinically significant pain symptoms. ...

[CITATION] A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia … -
LM Arnold, Y Lu, LJ Crofford, M Wohlreich, MJ … - Arthritis & Rheumatism, 2004
... 10 [completely interferes]) with general activity, mood ... Statistical Manual of Mental
Disorders, Fourth Edition ... severity of depressive and anxiety symptoms was ...

Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. -
DJ Goldstein, C Mallinckrodt, Y Lu, MA Demitrack - J Clin Psychiatry, 2002 - ncbi.nlm.nih.gov
... major depressive disorder, or any anxiety disorder as a ... Duloxetine was numerically
superior to fluoxetine on ... In general, duloxetine was well tolerated; 76% of ...

Efficacy of Duloxetine for the Treatment of Generalized Anxiety Disorder: Implications for Primary … -
H Koponen, C Allgulander, J Erickson, E Dunayevich … - Primary Care Companion to The Journal of Clinical Psychiatry, 2007 - pubmedcentral.nih.gov
... Inc. Efficacy of Duloxetine for the Treatment of Generalized Anxiety Disorder:
Implications for Primary Care Physicians. Hannu Koponen ...

Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active- … -
J Hartford, S Kornstein, M Liebowitz, T Pigott, J … - International Clinical Psychopharmacology, 2007 - intclinpsychopharm.com
... to-control, chronic worry, generalized anxiety disorder (GAD) is ... at visit 1. The
Covi Anxiety Scale score ... past 6 months; panic disorder, posttraumatic disorder ...

Source: Google Scholar
 

Duloxetine improves generalized anxiety disorder

Last Updated: 2007-05-08 14:21:19 -0400 (Reuters Health)

NEW YORK (Reuters Health) - The results of a study published in the April issue of the Journal of Clinical Psychiatry indicate that treatment with duloxetine, sold under the trade name Cymbalta, improves functioning and enhances the quality of life in patients with generalized anxiety disorder.

Dr. Jean Endicott, of Columbia School of Medicine, New York, and colleagues examined the effectiveness of duloxetine in patients with generalized anxiety disorder who participated in three studies.

In one study, the investigators conducted a 9-week fixed-dose trial of duloxetine treatment (60 or 120 mg) compared with placebo. In the other two studies, researchers compared a 10-week flexible dose of duloxetine treatment (60 to 120 mg) with placebo. The trials involved a total of 1,163 patients.

Article continues below and (thank you)

 

The improvement in patients treated with duloxetine was significantly greater compared with improvements in those treated with placebo, according to the results of tests that measured overall functioning, work performance, social life, and family and home responsibilities.

At the end of treatment, duloxetine patients were more likely to obtain a global functioning score of 5 or less, which is in the normal range of individuals without a psychiatric disorder, Endicott and colleagues report. "Across the studies, approximately 47 percent of duloxetine-treated patients and 28 percent of placebo-treated patients achieved this outcome."

Compared with placebo-treated patients, those treated with duloxetine also reported greater increases in quality of life, well-being and health.

The team concludes: "The consistency of duloxetine's efficacy in improving role functioning...demonstrates its ability to impact these essential patient outcomes associated with symptoms of generalized anxiety disorder."

SOURCE: Journal of Clinical Psychiatry, April 2007.

Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

 
 
 
Google
Web www.iconocast.com
 
 
Continue News With: News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

 © 2002-2006

Keywords:

Contact Iconocast